Controversy About the Cardiovascular Safety of Sibutramine

Overview

Journal Drug Saf

Specialties Pharmacology
Toxicology

Date 2010 Jun 18

PMID 20553062

Citations 1

Authors

Andre J Scheen

Affiliations

Soon will be listed here.

Citing Articles

The effect of sibutramine prescribing in routine clinical practice on cardiovascular outcomes: a cohort study in the United Kingdom.

Hayes J, Bhaskaran K, Batterham R, Smeeth L, Douglas I Int J Obes (Lond). 2015; 39(9):1359-64.

PMID: 25971925 PMC: 4551415. DOI: 10.1038/ijo.2015.86.

References

OFlaherty M, Ford E, Allender S, Scarborough P, Capewell S . Coronary heart disease trends in England and Wales from 1984 to 2004: concealed levelling of mortality rates among young adults. Heart. 2007; 94(2):178-81. DOI: 10.1136/hrt.2007.118323. View

Kaul S, Bolger A, Herrington D, Giugliano R, Eckel R . Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation. 2010; 121(16):1868-77. DOI: 10.1161/CIR.0b013e3181d34114. View

Goldfine A . Assessing the cardiovascular safety of diabetes therapies. N Engl J Med. 2008; 359(11):1092-5. DOI: 10.1056/NEJMp0805758. View

Harrison-Woolrych M, Ashton J, Herbison P . Fatal and non-fatal cardiovascular events in a general population prescribed sibutramine in New Zealand: a prospective cohort study. Drug Saf. 2010; 33(7):605-13. DOI: 10.2165/11532440-000000000-00000. View

Nissen S, Wolski K . Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007; 356(24):2457-71. DOI: 10.1056/NEJMoa072761. View

Gregg E, Cheng Y, Cadwell B, Imperatore G, Williams D, Flegal K . Secular trends in cardiovascular disease risk factors according to body mass index in US adults. JAMA. 2005; 293(15):1868-74. DOI: 10.1001/jama.293.15.1868. View

Perrio M, Wilton L, Shakir S . The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. Obesity (Silver Spring). 2007; 15(11):2712-22. DOI: 10.1038/oby.2007.323. View

Robinson J, Niswender K . What are the risks and the benefits of current and emerging weight-loss medications?. Curr Diab Rep. 2009; 9(5):368-75. DOI: 10.1007/s11892-009-0058-x. View

Caterson I, Coutinho W, Finer N, Van Gaal L, Maggioni A, Torp-Pedersen C . Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period. Obesity (Silver Spring). 2009; 18(5):987-94. DOI: 10.1038/oby.2009.327. View

10.

Rosengren A, Eriksson H, Hansson P, Svardsudd K, Wilhelmsen L, Johansson S . Obesity and trends in cardiovascular risk factors over 40 years in Swedish men aged 50. J Intern Med. 2009; 266(3):268-76. DOI: 10.1111/j.1365-2796.2009.02116.x. View

11.

Poirier P, Giles T, Bray G, Hong Y, Stern J, Pi-Sunyer F . Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition,.... Circulation. 2005; 113(6):898-918. DOI: 10.1161/CIRCULATIONAHA.106.171016. View

12.

Sharma B, Henderson D . Sibutramine: current status as an anti-obesity drug and its future perspectives. Expert Opin Pharmacother. 2008; 9(12):2161-73. DOI: 10.1517/14656566.9.12.2161. View

13.

Nisoli E, Carruba M . A benefit-risk assessment of sibutramine in the management of obesity. Drug Saf. 2003; 26(14):1027-48. DOI: 10.2165/00002018-200326140-00004. View

14.

Ford E, Ajani U, Croft J, Critchley J, Labarthe D, Kottke T . Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med. 2007; 356(23):2388-98. DOI: 10.1056/NEJMsa053935. View

15.

Finer N . Withdrawal of sibutramine. Editorial is judgment in advance of the facts. BMJ. 2010; 340:c1346. DOI: 10.1136/bmj.c1346. View

16.

Zalesin K, Franklin B, Miller W, Peterson E, McCullough P . Impact of obesity on cardiovascular disease. Endocrinol Metab Clin North Am. 2008; 37(3):663-84, ix. DOI: 10.1016/j.ecl.2008.06.004. View

17.

Rosengren A . Declining cardiovascular mortality and increasing obesity: a paradox. CMAJ. 2009; 181(3-4):127-8. PMC: 2717654. DOI: 10.1503/cmaj.090911. View

18.

Tziomalos K, Krassas G, Tzotzas T . The use of sibutramine in the management of obesity and related disorders: an update. Vasc Health Risk Manag. 2009; 5(1):441-52. PMC: 2686261. DOI: 10.2147/vhrm.s4027. View

19.

Greenway F, Caruso M . Safety of obesity drugs. Expert Opin Drug Saf. 2005; 4(6):1083-95. DOI: 10.1517/14740338.4.6.1083. View

20.

de Simone G, DAddeo G . Sibutramine: balancing weight loss benefit and possible cardiovascular risk. Nutr Metab Cardiovasc Dis. 2008; 18(5):337-41. DOI: 10.1016/j.numecd.2008.03.008. View